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Objective: To explore the anti-tumor activity of tanshinone IIA in combined with cyclo-
phosphamide against Lewismicewith lung cancer and the effect on cellular immune function.
Methods: Lewis tumor cells were inoculated subcutaneously into the right armpit of
mice in each group (n = 20) to establish Lewis lung cancer mice model. After model
establishment, mice in the model group were given normal saline by lavage, qd. Mice in
treatment I group were given intraperitoneal injection of Tan IIA, 15 mg/kg, qd. Mice in
treatment II group were given intraperitoneal injection of CTX, 25 mg/kg, qd. Mice in
treatment III group were given intraperitoneal injections of Tan IIA and CTX, in which
the administration method of Tan IIA was the same as in treatment I group, continuously
for 2 weeks, and the dosage of CTX was the same as in treatment II group, 24 h after
model establishment, every other day. Mice were sacriﬁced 2 weeks after establishment.
The tumor tissues were collected to calculate the anti-tumor rate. Immunohistochemistry
was used to detect the expressions of Bcl-2, Bax, VEGF, Angiostatin, and Endostatin.
FCM was used to detect T lymphocyte subsets in spleen and liver of mice.
Results: The tumor weight in treatment I, II, and III groups was signiﬁcantly lower than that
in the model group (P < 0.05). The tumor weight in treatment III group was signiﬁcantly
lower than that in treatment I and II groups (P< 0.05). The anti-tumor rate in treatment II and
III groups was signiﬁcantly higher than that in treatment I group (P< 0.05). Bcl-2 expression
in the tumor tissues of treatment I, II, and III groups was signiﬁcantly lower than that in the
model group (P< 0.05), while Bax expressionwas signiﬁcantly higher than that in themodel
group (P < 0.05). Bcl-2 expression in the tumor tissues of treatment I and II groups was
signiﬁcantly higher than that in treatment III group (P < 0.05), while Bax expression was
signiﬁcantly lower than that in treatment III group (P < 0.05). CD4+ and CD4+/CD8+ in
treatment I, II, and III groups were signiﬁcantly higher than those in the model group
(P< 0.05). CD4+ in treatment III groupwas signiﬁcantly higher than that in treatment I and II
groups (P< 0.05), while CD4+/CD8+ was signiﬁcantly higher than that in treatment II group
(P < 0.05). The comparison of CD8+ among each group was not statistically signiﬁcant
(P> 0.05). NK cell activity in treatment I, II, and III groups was signiﬁcantly higher than that
in themodel group (P< 0.05). NK cell activity in treatment III groupwas signiﬁcantly higher
than that in treatment I and II groups (P < 0.05).
Conclusions: Tan IIA in combined with CTX can down regulate Bcl-2 expression in
lung cancer tissues, up regulate Bax expression, inhibit the neovascularization of tumor
tissues, and enhance the immunological function, with a signiﬁcant anti-tumor activity.ticle under the CC BY-NC-ND license (http://
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Lung cancer is a common malignant tumor of respiratory
system in the clinic, with an increasing morbidity due to the al-
terations of modern environment and life style, and has been one
of the diseases which can severely threaten the human life and
health [1–3]. The pathogenesis of lung cancer is not yet clear.
Some scholars argue that its pathogenesis is closely associated
with the long-term heavy smoking [4]. According to the
statistics [5], in recent 50 years, the morbidity and fatality rate
of lung cancer in males rank the ﬁrst place among all
malignant tumors. With the continuous maturity of radiotherapy
and chemotherapy technology, the efﬁcacy by medicine of lung
cancer is improved greatly, but the total 5-year survival rate is
only 10%–15%, with a poor long-term efﬁcacy [6]. A large
amount of researches verify that [7] operation, radiotherapy, and
chemotherapy can produce a certain effect on the
immunological function; therefore, how to effectively treat lung
cancer and reduce the effect on immunological function as
much as possible has been the hot tissue of clinical research.
CTX, a common anti-tumor drug in the clinic, can intervene
DNA and RNA functions in tumor cells, with a wide application
[8,9]. Tan IIA can signiﬁcantly resist the atherosclerosis, inhibit
the platelet aggregation, kill various tumor cells, and promote
their apoptosis [10]. In order to observe the anti-tumor activity
of Tan IIA in combined with CTX against lung cancer mice and
the effect on cellular immune function, C57BL/6J mice were
selected to establish Lewis lung cancer mice model. After model
establishment, mice were given Tan IIA and CTX to observe its
anti-tumor activity against Lewis mice with lung cancer and the
effect on T lymphocyte subsets.2. Materials and methods
2.1. Experimental animals
A total of 80 male C57BL/6J mice (18–20 g), SPF, were
obtained from Beijing HFK Bioscience Co. Ltd. The animals
were housed under standard conditions of temperature (20 ± 2)
C and relative humidity (36%), and had free access to diet and
water. All the experiments were performed in the Animal
Experimental Center of Wuhan University. The animals were
treated and cared for strictly in accordance with the guidelines
recommended by the Laboratory Animal Administration Rules.
The experimental protocol was approved by our departmental
ethics committee.
2.2. Drugs and chemicals
Tan IIA sulfonate sodium injection was purchased from
Shanghai No. 1 Biochemical and Pharmaceutical Co., Ltd.
(Speciﬁcation: 10 mg/2 mL, Approval No. H31022558). CTX
injection was purchased from Jiangsu Hengrui Medicine Co.,
Ltd. (Speciﬁcation: 0.2 g/piece, Approval No. H32020857).
Lewis lung cancer cell lines were provided by the Immunology
Department of China Medical University. The anti-mice CD4
kits and anti-CD8 monoclonal antibodies (marked by PE) were
purchased from BD Company, US. BBSDSC super clean bench
was purchased from Shanghai Biboase. Olympus biological
microscope (Japan), AnKe80 -ZC desk centrifuge, 301- 268.001
histotome, and Leica-DM2500 B microscope (German) werealso purchased. Image-pro plus 6.0 image processing software
was adopted.
2.3. Model establishment
Lewis lung cancer cell lines were melted at 37 C, and
centrifuged at 14 000 r/min. The supernatant was abandoned,
and the suspension was diluted with cell concentration of
1 × 107/mL for preservation. The prepared cell suspension
(0.2 mL) was inoculated subcutaneously into the right armpit of
mice, with two generations. After inoculation, the mice were
randomized into the model group, treatment I, II, and III groups
with 20 mice in each group. After model establishment, mice in
the model group were given normal saline by lavage, qd. Mice
in treatment I group were given intraperitoneal injection of Tan
IIA, 15 mg/kg, qd. Mice in treatment II group were given
intraperitoneal injection of CTX, 25 mg/kg, qd. Mice in treat-
ment III group were given intraperitoneal injections of Tan IIA
and CTX, in which the administration method of Tan IIA was
the same as in treatment I group, continuously for 2 weeks, and
the dosage of CTX was the same as in treatment II group, 24 h
after model establishment, every other day.
2.4. Observation indicators
Mice were sacriﬁced 2 weeks after establishment. The tumor
tissues were collected to calculate the anti-tumor rate. Anti-
tumor rate (%) = (average tumor weight in the model
group − average tumor weight in the treatment group)/average
tumor weight in the model group × 100%. Immunohistochem-
istry was used to detect the expressions of Bcl-2, Bax, VEGF,
Angiostatin, and Endostatin. The spleen of mice in each group
was collected under a sterile condition. The spleen cell sus-
pension was prepared with cell concentration of 1 × 107/mL.
FCM was used to detect T lymphocyte subsets in spleen of mice.
2.5. Statistical analysis
SPSS 16.0 software was used for the statistical analysis. The
measurement data were expressed as mean ± SD, and t test was
used. P < 0.05 was regarded as statistically signiﬁcant.
3. Results
3.1. Comparison of the anti-tumor rate among four
groups
The tumor weight in treatment I, II, and III groups was
signiﬁcantly lower than that in the model group (P < 0.05). The
tumor weight in treatment III group was signiﬁcantly lower than
that in treatment I and II groups (P < 0.05). The anti-tumor rate
in treatment II and III groups was signiﬁcantly higher than that
in treatment I group (P < 0.05). The comparison of anti-tumor
rate between treatment II and III groups was not statistically
signiﬁcant (P > 0.05) (Table 1).
3.2. Comparison of Bcl-2 and Bax expressions in the
tumor tissues among four groups
Bcl-2 expression in the tumor tissues of treatment I, II, and III
groups was signiﬁcantly lower than that in the model group
Table 1
Comparison of the tumor weight and anti-tumor rate among four groups (n = 20).
Groups Tumor weight (g) Anti-tumor rate (%) Bcl-2 Bax
Treatment I group 2.49 ± 0.19*# 25.8*# 45.78 ± 5.42*# 39.55 ± 3.92*#
Treatment II group 1.21 ± 0.39*# 50.1* 35.82 ± 4.24*# 43.47 ± 4.21*#
Treatment III group 1.08 ± 0.48* 58.3* 25.15 ± 4.11* 52.13 ± 5.36*
Model group 3.34 ± 0.20 0.0 59.72 ± 3.48# 31.85 ± 8.61#
*P < 0.05, when compared with the model group; #P < 0.05, when compared with treatment III group.
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that in the model group (P < 0.05). Bcl-2 expression in the
tumor tissues of treatment I and II groups was signiﬁcantly
higher than that in treatment III group (P < 0.05), while Bax
expression was signiﬁcantly lower than that in treatment III
group (P < 0.05) (Table 1).
3.3. Comparison of VEGF, Angiostatin, and Endostatin
expressions in the tumor tissues among four groups
VEGF expression in treatment I, II, and III groups was
signiﬁcantly lower than that in the model group (P < 0.05),
while Angiostatin and Endostatin expressions were signiﬁcantly
higher than those in the model group (P < 0.05). VEGF
expression in treatment I and II groups was signiﬁcantly higher
than that in treatment III group (P < 0.05), while Angiostatin
and Endostatin expressions were signiﬁcantly lower than those
in treatment III group (P < 0.05) (Table 2).
3.4. Comparison of the immunological function among
four groups
CD4+ and CD4+/CD8+ in treatment I, II, and III groups were
signiﬁcantly higher than those in the model group (P < 0.05).
CD4+ in treatment III group was signiﬁcantly higher than that in
treatment I and II groups (P < 0.05), while CD4+/CD8+ was
signiﬁcantly higher than that in treatment II group (P < 0.05).
The comparison of CD8+ among each group was not statistically
signiﬁcant (P > 0.05). NK cell activity in treatment I, II, and III
groups was signiﬁcantly higher than that in the model group
(P < 0.05). NK cell activity in treatment III group was signiﬁ-
cantly higher than that in treatment I and II groups (P < 0.05)
(Table 3).Table 2
Comparison of VEGF, Angiostatin, and Endostatin expressions in the tumor
Groups VEGF
Treatment I group 22 525.08 ± 17 665.99*#
Treatment II group 19 260.64 ± 5 414.20*#
Treatment III group 11 512.88 ± 5 568.63
Model group 59 089.63 ± 17 740.77#
*P < 0.05, when compared with the model group; #P < 0.05, when compa
Table 3
Comparison of T lymphocyte subsets levels among four groups (%) (n = 20
Groups CD4+ C
Treatment I group 15.16 ± 1.79*# 15.83
Treatment II group 12.95 ± 2.08*# 16.65
Treatment III group 22.25 ± 6.82* 15.49
Model group 09.11 ± 2.19 14.60
*P < 0.05, when compared with the model group; #P < 0.05, when compa4. Discussion
Lung cancer is a common malignant tumor of respiratory
system in the clinic, occurring more in males than in females,
and ranks the ﬁrst place of malignant tumor death among the
urban population [11]. Non-small cell lung cancer is a common
type in the clinic, including large cell carcinoma, adenocarci-
noma, and squamous-cell carcinoma, whose cell division is
slower than other cancer cells, with later spreading and metas-
tasis [12–15]. Due to its concealment, most non-small cell lung
cancer is discovered on physical examination, but already pro-
gresses into the middle and advanced stage, with a low 5-year
survival rate [16–18]; therefore, how to conduct an effective
treatment is of great signiﬁcance in improving the patients'
survival.
Multiple factors are involved in the lung cancer pathogenesis
which is not yet completely clariﬁed [19]. Some scholars argue
that [20] the imbalance of cell apoptosis and proliferation may
be a main factor for developing lung cancer. Cell apoptosis is
an initiative and physiological death mechanism of cell itself,
and is regulated by the apoptosis inhibiting factor and pro-
apoptosis factor. Bcl-2 and Bax belong to Bcl-2 family genes,
and are closely associated the occurrence of various humor tu-
mors [21]. Bcl-2 a proto-oncogene cloned from the follicular B-
cell non-Hodgkin lymphoma, and can inhibit the cell apoptosis,
while Bax is a pro-apoptosis gene, and can resist Bcl-2 [22]. The
results in the study showed that Bcl-2 expression in treatment I,
II, and III groups was signiﬁcantly lower than that in the model
group (P < 0.05), while Bax expression was signiﬁcantly higher
than that in the model group (P < 0.05), suggesting that the 3
treatment protocols can down regulate Bcl-2 expression, and up
regulate Bax expression. The results in the study also showed
that Bcl-2 expression in the tumor tissues of treatment I and IItissues among four groups (n = 20).
Angiostatin Endostatin
30 758.38 ± 6 561.57*# 26 022.40 ± 8 105.76*#
31 754.67 ± 7 142.30*# 25 895.04 ± 13 523.83*#
47 142.17 ± 10 476.41 28 009.05 ± 10 055.47
13 319.41 ± 4 504.00# 1 956.03 ± 2 348.28#
red with treatment III group.
).
D8+ CD4+/CD8+ NK
± 5.41 1.17 ± 0.18* 27.09 ± 0.06*#
± 1.81 0.86 ± 0.24*# 26.50 ± 0.05*#
± 4.65 1.37 ± 0.35* 52.53 ± 0.16*
± 3.30 0.62 ± 0.46* 19.62 ± 0.04
red with treatment III group.
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(P < 0.05), while Bax expression was signiﬁcantly lower than
that in treatment III group (P < 0.05), indicating that Tan IIA in
combined with CTX can promote the lung cancer cell apoptosis,
with a more signiﬁcant effect.
Some scholars argue that [22] when the tumor diameter is
greater than 1 mm, the surrounding tissues are unable to
provide the required nutrition for its growth. The sequential
growth of tumor must depend on new blood vessels to
maintain the nutrition supply, otherwise, degeneration will
occur in the tumor cells. The tumor angiogenesis is a multi-
step complicated process, including vascular endothelial cell
proliferation and migration, and extracellular matrix degrada-
tion. VEGF is an important factor to promote the angiogenesis,
while Angiostatin and Endostatin are the main inhibiting factors
for angiogenesis [23]. The results in the study showed that VEGF
expression in treatment I, II, and III groups was signiﬁcantly
lower than that in the model group (P < 0.05), while
Angiostatin and Endostatin expressions were signiﬁcantly
higher than those in the model group (P < 0.05), suggesting
that the 3 treatment protocols can inhibit the angiogenesis of
tumor tissues. The results in the study also showed that VEGF
expression in treatment I and II groups was signiﬁcantly
higher than that in treatment III group (P < 0.05), while
Angiostatin and Endostatin expressions were signiﬁcantly
lower than those in treatment III group (P < 0.05), indicating
that Tan IIA in combined with CTX can better effectively
inhibit the angiogenesis of tumor tissues in order to reach the
goal of anti-tumor. In the study, the anti-tumor rate in treat-
ment III group was the highest, which is associated with the
effective inhibition on the tumor angiogenesis by Tan IIA and
CTX.
Some experiments verify that [24,25] the multiple immune
escape mechanism formed in the growth process of cancer
cells is an important factor for the continuous occurrence and
development of tumor cells; therefore, the immunological
function plays a vital role in the tumor treatment process. The
results in the study showed that CD4+ in treatment III group
was signiﬁcantly higher than that in treatment I and II groups
(P < 0.05), while CD4+/CD8+ was signiﬁcantly higher than
that in treatment II group (P < 0.05); moreover, NK cell
activity in treatment III group was signiﬁcantly higher than
that in treatment I and II groups (P < 0.05), indicating that
this treatment protocol can effectively enhance the
immunological function to strengthen the anti-tumor effect.
In conclusion, Tan IIA in combined with CTX can down
regulate Bcl-2 expression in lung cancer tissues, up regulate Bax
expression, inhibit the neovascularization of tumor tissues, and
enhance the immunological function, with a signiﬁcant anti-
tumor activity.
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